MedPath

A Clinical Trial to study the effect of Ulipristal Acetate Tablets 30 mg in Women requiring emergency contraceptio

Phase 3
Completed
Registration Number
CTRI/2019/09/021343
Lead Sponsor
Synokem Pharmaceuticals Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
102
Inclusion Criteria

1. Women aged >=18 & <= 40 years of age.

2. History of regular menstrual cycles (mean length of 24-40 days with intra-individual variation of ±5 days).

3. Woman reports that all acts of unprotected coitus during the current cycle are within 72 hours (for reference product) or 120 hours (for test product) prior to enrolment.

4. Request for emergency contraceptive within 72 hours (for reference product) or 120 hours (for test product) after unprotected coitus, as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure.

Exclusion Criteria

1. Women < 18 & >40 years of age.

2. History of hypersensitivity to the study drug or reference drug or related products.

3. Patients with history of lactose intolerance.

4. Use of hormonal methods of contraception during the current or previous two cycles or whose partner was sterilized.

5. Participation in a clinical trial with an investigation drug within 30 days preceding day 1 of this study.

6. Women reports that all acts of unprotected coitus during the current cycle are more than 120 hours prior to enrolment.

7. Women who are pregnant or breastfeeding.

8. History of severe hepatic impairment.

9. History of severe asthma insufficiently controlled by oral glucocorticoids.

10. History of acute porphyria.

11. Any other condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pregnancy rate in women who received emergency contraception within 72 hours after unprotected sexual intercourse. <br/ ><br> <br/ ><br>Pregnancy rate women who received emergency contraception within 120 hours after unprotected sexual intercourse (only for Test product). <br/ ><br> <br/ ><br>Detection of early pregnancy shall be assessed by UPT (urine pregnancy test) and results will be recorded as per investigatorâ??s observation. <br/ ><br>Timepoint: 120 Hours for Test Product <br/ ><br>72 Hours for Reference Product <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Pregnancy rate in women who received emergency contraception between used 48 and â?¤ 72 hours after unprotected sexual intercourse. <br/ ><br> <br/ ><br>Pregnancy rate in women who received emergency contraception between 72 and â?¤ 96 hours after unprotected sexual intercourse (For Test product only). <br/ ><br> <br/ ><br>Pregnancy rate in women who received emergency contraception between 96 and â?¤ 120 hours after unprotected sexual intercourse (For Test product only). <br/ ><br>Timepoint: 120 Hours for Test Product <br/ ><br>72 Hours for Reference Product
© Copyright 2025. All Rights Reserved by MedPath